EAU guidelines on penile cancer.

Diagnosis and management of premalignant penile lesions. Ther Adv Urol (2011) 0.83

Imaging in primary penile cancer: current status and future directions. Eur Radiol (2009) 0.81

Endoscopic inguinal lymph node dissection for penile carcinoma: the developing of a novel technique. World J Urol (2009) 0.78

Investigating the role of SPECT/CT in dynamic sentinel lymph node biopsy for penile cancers. Eur J Nucl Med Mol Imaging (2017) 0.75

The role of lymph node fine-needle aspiration in penile cancer in the sentinel node era. Adv Urol (2011) 0.75

Penile lichen sclerosus: An enigmatic and challenging disease. Urol Ann (2015) 0.75

Penile cutaneous horn: An enigma-newer insights and perspectives. Indian J Sex Transm Dis (2015) 0.75

[The significance of inguinal lymphadenectomy in carcinoma of the penis]. Urologe A (2006) 0.75

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54

EAU guidelines on prostate cancer. Eur Urol (2007) 6.30

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2013) 4.65

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol (2013) 4.58

2007 Guideline for the management of ureteral calculi. Eur Urol (2007) 3.98

EAU guidelines on penile cancer: 2014 update. Eur Urol (2014) 3.86

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55

European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93

European Association of Urology guidelines on priapism. Eur Urol (2013) 2.41

EAU guidelines on penile curvature. Eur Urol (2012) 2.40

Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 2.31

How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol (2004) 2.29

Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23

Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14

Guidelines on Testicular Cancer: 2015 Update. Eur Urol (2015) 2.11

EAU guidelines on surgical treatment of urinary incontinence. Eur Urol (2012) 2.05

EAU guidelines on chronic pelvic pain. Eur Urol (2009) 1.97

EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96

EAU guidelines on prostate cancer. Eur Urol (2005) 1.88

EAU guidelines on vesicoureteral reflux in children. Eur Urol (2012) 1.76

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73

Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol (2013) 1.71

EAU guidelines on urological trauma. Eur Urol (2005) 1.70

[EAU guidelines on prostate cancer]. Actas Urol Esp (2009) 1.68

Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 1.67

Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. J Urol (2011) 1.64

EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol (2004) 1.47

EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol (2001) 1.46

The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol (2013) 1.45

Sequential treatment for recurrent localized prostate cancer. J Surg Oncol (2008) 1.45

Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2008) 1.45

[Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]. Actas Urol Esp (2011) 1.41

[Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994]. Ned Tijdschr Geneeskd (1996) 1.40

[Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression]. Actas Urol Esp (2011) 1.39

The clinical implications of the prostate cancer prevention trial. BJU Int (2003) 1.38

[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation]. Ned Tijdschr Geneeskd (1996) 1.38

[Less mutilating treatment of penile carcinoma]. Ned Tijdschr Geneeskd (2005) 1.35

EAU guidelines on iatrogenic trauma. Eur Urol (2012) 1.34

EAU Guidelines on Urethral Trauma. Eur Urol (2010) 1.29

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol (2001) 1.27

Upper urinary tract cancer: location is correlated with prognosis. Eur Urol (2005) 1.24

EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol (2012) 1.23

A trial of consent procedures for future research with clinically derived biological samples. Br J Cancer (2009) 1.22

EAU guidelines on renal transplantation. Eur Urol (2005) 1.22

EAU guidelines on primary urethral carcinoma. Eur Urol (2013) 1.22

Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol (1999) 1.22

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol (2008) 1.21

EAU Guidelines on Penile Cancer. Eur Urol (2004) 1.19

[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. Actas Urol Esp (2011) 1.19

Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. J Urol (2005) 1.18

EAU guidelines on paediatric urology. Eur Urol (2001) 1.16

Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. J Urol (2004) 1.16

Morbidity of dynamic sentinel node biopsy in penile carcinoma. J Urol (2005) 1.15

Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol (2005) 1.14

EAU guidelines on robotic and single-site surgery in urology. Eur Urol (2013) 1.13

Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol (2010) 1.12

Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol (1994) 1.10

[The course of prostatic carcinoma]. Ned Tijdschr Geneeskd (1995) 1.07

[Iodine-125 implantation in localized cancer of the prostate; too early for rejoicing]. Ned Tijdschr Geneeskd (1998) 1.07

[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. Actas Urol Esp (2012) 1.02

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int (2002) 1.02

Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl (2000) 1.01

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol (2003) 1.00

Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol (2003) 0.99

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol (2002) 0.99

EAU guidelines on chronic pelvic pain. Eur Urol (2004) 0.99

Intraoperative radioguidance with a portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. Eur J Nucl Med Mol Imaging (2009) 0.98

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95

Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol (2012) 0.94

Origin of trisomy 21 in Down syndrome cases from a Spanish population registry. Ann Genet (2000) 0.94

Photodynamic therapy of localised prostatic cancer. Lancet (1990) 0.93

Diagnosis and clinical presentation of premalignant lesions of the penis. Scand J Urol Nephrol Suppl (2000) 0.93

Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys (1998) 0.93

EAU guidelines on surgical treatment of urinary incontinence. Actas Urol Esp (2013) 0.92

Laser therapy for carcinoma in situ of the penis. J Urol (2001) 0.92

Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol (2005) 0.91

Dynamic sentinel node biopsy for penile cancer: reliability of a staging technique. J Urol (2002) 0.89

The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol (1995) 0.89

Guidelines on erectile dysfunction. Eur Urol (2002) 0.89

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. Eur J Surg Oncol (2013) 0.88

Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam. J Urol (2005) 0.87

Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol (2014) 0.87

A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int (2003) 0.86

[EAU Guidelines on Urinary Incontinence]. Actas Urol Esp (2011) 0.86

Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys (2001) 0.86

Pseudomyxoma peritonei and the urinary tract: involvement and treatment related complications. J Surg Oncol (2006) 0.86

Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. J Urol (2011) 0.86

Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol (2005) 0.85

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer (2003) 0.85

Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours. Histopathology (2008) 0.85

Management of clinically node negative penile carcinoma: improved survival after the introduction of dynamic sentinel node biopsy. J Urol (2003) 0.84

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer (2013) 0.84

Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol (2001) 0.84

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology (2002) 0.84